Interview with Thea Pharma’s Susan Benton about Innovations in Eye Care and the FDA Approval of Iyuzeh – Xtalks Life Science Podcast Ep. 94

In this week’s Xtalks Life Science podcast episode, Ayesha and the editorial team spoke with Susan Benton, Country Manager at Thea Pharma, an eye care company that focuses on developing innovative eye care treatments to help further the future of ophthalmic treatment.

Thea Pharma recently won FDA approval for its latest eye care product Iyuzeh for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Iyuzeh is the first and only preservative-free formulation of the medication latanoprost in the US.

To talk more about the new FDA approval for Iyuzeh and about the great work being done at Thea Pharma, tune in to hear this informative and insightful interview with Susan Benton, who has more than 25 years of global commercial and business development experience in ophthalmic pharmaceuticals, and has been responsible for the launch and commercialization of more than 15 products over the course of her career.

Read more at: Iyuzeh Approved for Reduction of Elevated Intraocular Pressure for Patients with Open-Angle Glaucoma or Ocular Hypertension

The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.